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Interstitial lungdisease(ILD) isan increasinglyrecognized complicationofrheumatoidarthritis (RA) contributing to signiﬁcantly
increased morbidity and mortality. Diagnosis can be challenging since patients are unlikely to report dyspnea due to an overall
decrease in physical activity with advanced arthritic symptoms. Additionally, infections, drug toxicity, and environmental toxins
can mimic ILD, creating signiﬁcant diagnostic dilemmas for the clinician. In this paper we will explore an eﬀective clinical
algorithm for the diagnosis of RA-ILD. We will also discuss features of drug-related toxicities, infections, and environmental
toxins that comprisethe main entities in the diﬀerential diagnosisof RA-ILD. Finally, we will explore the knownand experimental
treatment options that may have some beneﬁt in the treatment of RA-ILD.
1.Introduction
It has been estimated that nearly 50% of rheumatoid
arthritis (RA) patients will develop some form of respiratory
abnormality during their lifetime [1, 2]. In fact, one study
by Toyoshima et al. placed pulmonary disease as the
second leading cause of death in RA accounting for nearly
20% of the mortality [3] .W h i l et h e r ea r eam y r i a do f
pulmonary complications associated with RA (Table 1), the
most debilitating remains rheumatoid arthritis-associated
interstitial lung disease (RA-ILD).Advancements in imaging
technology have improved our ability to diagnose RA-
ILD, and what once was thought to be a relatively rare
complication is now suspected to aﬀect 20–30% of RA
patients [4].
In this paper, we will discuss the initial evaluation of
suspected RA-ILD focusing on screening algorithms and
radiologic features of the disease. However, screening and
diagnosis of RA-ILD is only one aspect of care. Once the
presence of RA-ILD is certain, the challenge for clinicians
comes in distinguishing an exacerbation of RA-ILD from
infection, drug toxicity, or a host of other comorbid disease
entities. We will explore a practical approach to the workup
and treatment of a clinical deterioration in the established
RA-ILD patient, and the following case history will serve
as a framework for this discussion highlighting some of the
inherent challenges.
2.Case Discussion
A 64-year-old woman was originally diagnosed with RA in
1986, and over the next several years her treatment regimen
escalated from nonsteroidal anti-inﬂammatory medications
with gold salts to D-penicillamine and methotrexate (MTX).
In 2000, she was started on etanercept. Her arthritis symp-
toms were manageable on a regimen of etanercept and
nonsteroidal anti-inﬂammatory medications, but after a few
years of therapy she began to develop a mild non-productive
cough but no noticeable dyspnea on exertion. In 2007,
she was admitted to the hospital with acute renal failure.
A kidney biopsy showed focal and segmental sclerosis. A
chest X-ray from that hospitalization was abnormal, and a
high-resolution chest CT (HRCT) demonstrated increased
reticular markings consistent with an interstitial lung disease
(Figure 1). She was started on peritoneal dialysis and2 Pulmonary Medicine
Table 1: Respiratory complications of rheumatoid arthritis.
Lung structure Disease manifestations
Lung parenchyma
Interstitial lung disease (ILD)
Usual interstitial pneumonitis (UIP)
Nonspeciﬁc interstitial pneumonitis (NSIP)
Bronchiolitis obliterans with organizing pneumonia (BOOP)
Lymphocytic interstitial pneumonitis (LIP)
Desquamative interstitial pneumonitis (DIP)
Diﬀuse alveolar damage (DAD)
Drug-induced pneumonitis
Rheumatoid nodules (necrobiotic nodules)
Caplan’s syndrome (silicosis associated with RA)
Infectious complications
Airways
Chronic obstructive pulmonary disease (COPD)
Bullous emphysema
Bronchiectasis
Obliterative bronchiolitis (Constrictive bronchiolitis)
Pleura
Pleuritis
Pleural eﬀusion
Spontaneous pneumothorax
Vascular Pulmonary hypertension
Diﬀuse alveolar hemorrhage
Extrapulmonary Diaphragm weakness
Cricoarytenoid arthritis with extrathoracic obstruction
prednisone for the renal failure but did not undergo any
further evaluation of her pulmonary inﬁltrates.
Hercoughpersisted, and she eventuallybecame dyspneic
climbing a ﬂight of stairs. She was ﬁnally referred for an
evaluation by a pulmonologist. Additional ﬁndings obtained
at her initial visit included a history of myocardial infarction
in 2001 and hypothyroidism treated with levothyroxine. She
also kept two cockatiels as pets. She had no other hobbies
or environmental exposures, and she was never a smoker.
In addition to her cough, dyspnea, and arthritis pain, she
also admitted night sweats over the past 6months, but no
weight loss. Her exam revealed a low-grade fever at 99.6F,
and she had bibasilar crackles but no digital clubbing. Her
oxygen saturation was 100% at rest. Pulmonary function
tests (PFTs) were obtained which demonstrated a preserved
totallungcapacityandforcedvitalcapacityat106%and90%
of predicted, respectively, but her diﬀusing capacity (DLCO)
was moderately reduced at 61% of predicted.
In summary, this was a woman with long-standing
RA greatly increasing her risk for RA-ILD. However, she
also had a history of using several medications (gold
salts, D-penicillamine, methotrexate and etanercept) all of
which have been associated with drug-induced interstitial
pneumonitis.In addition,she had exposure tocockatielsthat
couldinduceanunrelated hypersensitivity pneumonitis.Her
low-grade fevers and night sweats in the setting of chronic
immunosuppression could also suggest a possible chronic
infectious etiology or even an occult malignancy. Finally, she
hadahistory ofamyocardialinfarction andrenalfailure,and
she was now on peritoneal dialysis. She had no record of an
echocardiogram since 2001, so a possible coexistent medical
problem could account for her symptoms of dyspnea and
cough.
3.Establishing aDiagnosis ofRA-ILD
Although our index case is representative of a standard
referral to our practice, the majority of cases of RA-
ILD are uncovered following patient complaints to their
primarycarephysicianorrheumatologistregardingtheonset
of progressive dyspnea on exertion. A growing number
of rheumatology practices are facilitating a standardized
screening algorithm for RA-ILD; however, the most cost-
eﬀective approach to screening has not been universally
established [5].
In the era prior to the routine use of HRCT, the
prevalence of RA-ILD was about 1–5% based on clinical
exam and chest X-ray [6, 7]. In contrast, histological analysis
of lung tissue from RA patients found the presence of
pulmonary interstitial abnormalities in roughly 80% of
patients [8]. A more recent clinical study employing HRCT
also detected abnormalities in 80% of patients evaluated
for dyspnea; however, only about 25% of these changes
were consistent with ILD [9]. Additional ﬁndings included
bronchiectasis, bronchiolitis, and pulmonary nodules. Sim-
ilarly, other studies utilizing HRCT also found that only
about 20–30% of symptomatic patients had ground glassPulmonary Medicine 3
(a)
(b)
Figure 1: HRCT demonstrating predominantly reticular ﬁndings
( a )a sw e l la sg r o u n dg l a s sc h a n g e s( b ) .
opacities or increased reticular markings consistent with ILD
[4, 10].Given thepoor sensitivity of chest X-rayand the high
prevalence of abnormalities that do not always correlate to
clinical disease on HRCT, we do not recommend imaging as
an initial screening tool in asymptomatic patients.
Pulmonary function testing, and more speciﬁcally the
DLCO, appears to be the most sensitive test available to
screen for the presence of RA-ILD. Similar to our index
case, Dawson et al. found that 80% of patients with RA
had a reduced DLCO, while only 5–15% of patients had
a purely restrictive defect on spirometry [10]. While the
D L C Om a yb eh i g h l ys e n s i t i v ef o rR A - I L D ,t h es p e c i ﬁ c i t y
is lacking due to the prevalence of emphysema that can
destroy vascular beds thus aﬀecting the DLCO. In fact,
Geddes et al. reported obstructive spirometry ﬁndings in
more than 80% of RA patients in the form of bronchiectasis,
constrictive bronchiolitis, or emphysematous changes [11].
These obstructivedisordersalso appearto beatleastpartially
the eﬀect of the disease process since obstructive airways
disease in a nonsmoking RA population was much higher
than a nonsmoking control population [12]. Additionally
about25%ofpatientshavecricoarytenoidjointinvolvement,
and although it is usually asymptomatic, it can evolve,
sclerosing the joint leading to hoarseness, pain, and upper
airway obstructive respiratory symptoms [13].
Despite the fact that emphysema alone may decrease the
DLCO in the absence of RA-ILD,we still recommend follow-
up imaging when the DLCO is reduced to less than 70% of
predicted, especially in the absence of other abnormalities
in the PFTs. This is based on the increasing recognition
of “pseudo-normal PFTs” created by combined pulmonary
ﬁbrosis and emphysema in the idiopathicpulmonary ﬁbrosis
(IPF) population [14]. In several studies, up to 40% of
patients had radiographic evidence of emphysema and
pulmonary ﬁbrosis on HRCT. However, they had FVC and
T L Cv a l u e st h a tw e r en o r m a lo ro n l yh a dab o r d e r l i n e
restrictive defect, and the FEV1/FVC ratio was often normal
or only mildly reduced even with radiographic evidence of
severe emphysema [14–16]. In this subset of patients, there
was a uniform decrease in the DLCO (less than 40% in
most studies) that was often out of proportion to the rest
of the PFT abnormalities. Considering that there is a high
prevalence of tobacco use in the RA population, this pattern
ofcombinedpulmonary ﬁbrosisand emphysema maybejust
as common as that seen in IPF; however, further studies are
needed [17].
Unfortunately, routine pulmonary function tests on
every RA patient have not been established as a cost-eﬀective
approach toscreening forpulmonary disease [18].Consider-
ing that a number of patients will have abnormalities that do
not correlate with clinical disease, we believe that the history
andphysicalremainthevanguardsofclinicalevaluationuntil
further studies of costeﬀectiveness are presented [11]. We
advocate that each clinic visit include a brief inquiry into the
presence of cough or mild dyspnea when climbing a ﬂight
of stairs or on an incline, as well as clinical examination
for pulmonary crackles or digital clubbing although these
are usually only found in advanced disease [19]. Additional
patient factors that should increase the suspicion for RA-
ILD include sex, anti-CCP levels, and smoking status. In
epidemiologic studies, men are much more likely than
women to develop RA-ILD [20]. High levels of anti-CCP
antibodies have been associated with pulmonary ﬁbrosis,
and tobacco abuse (>25 pack years) may have the strongest
association with the development of RA-ILD with an odds
ratio of 3.8 [21, 22].
In summary, if dyspnea or cough is present, a complete
setofpulmonarytestsisindicatedincludingspirometry, lung
volumes,and DLCO(Figure2).ADLCOreducedtolessthan
70%ofpredictedshouldbethethreshold forfurtherimaging
with HRCT.
4.RadiologicEvaluationand Histopathology
The presence of bibasilar, symmetrical, ground glass inﬁl-
trates, increased reticular markings, or honeycombing on
HRCT is highly suggestive of ILD [23]. There can be a host
of other ﬁndings including pleural involvement, rheumatoid
nodules, bronchiectasis, emphysema, or even bronchiolitis
withorwithoutconsolidation[24,25].In regards toRA-ILD,
the radiologic ﬁndings doappear to correlatereasonably well
with the histopathological subtype, and therefore they carry
some prognostic signiﬁcance.4 Pulmonary Medicine
Initial screening History directed at dyspnea on exertion on stairs
or an incline
Exam for pulmonary crackles or digital clubbing
Complete pulmonary function tests Yearly screen for symptoms
Absent Present
Assess for other causes of
dyspnea
HRCT chest
Reticular markings without ground
glass opacities
Predominantly ground
glass opacities
Review medication history
Trial discontinuation of any
potential oﬀenders
Screen for
environmental
toxins
Screen for possible
infection
Additional treatment as indicated
Serum precipitins for
suspected allergens
DLCO <70% predicted DLCO >70% predicted
Probable UIP excludes
other causes as below and
initiates treatment as indicated
Possible NSIP exclude other possibilities
Repeat PFTs and HRCT in
3 months
Bronchoscopy with bronchoalveolar lavage
Culture for AFB, fungus, bacteria, and pneumocystis
Cell count for eosinophilia or lymphocytosis
Flow cytometry for CD4 : CD8 ratio
Transbronchial biopsies if hypersensitivity pneumonitisis possible
Figure 2: Diagnostic algorithm for the evaluation of rheumatoid arthritis.
Usual interstitial pneumonitis (UIP) is the predominant
histological ﬁnding in RA-ILD aﬀecting more than 50% of
patients [26, 27]. UIP is the same histological subtype that
underlies the end-stage lung disease idiopathic pulmonary
ﬁbrosis (IPF), and consequently it carries with it a relatively
similar prognosis. It appears that survival is somewhat
improved in patients with UIP in RA-ILD as opposed to
IPF, but 5-year survival is estimated to be less than 50% [28,
29]. In studies comparing HRCT ﬁndings with pathological
conﬁrmation of UIP, reticular markings and/or peripheral
honeycombing are highly sensitive for UIP [24, 26]. There
are a few instances in which HRCT features consistent with
UIP were actually found to be ﬁbrotic nonspeciﬁc interstitial
pneumonitis (ﬁbrotic NSIP) on pathological examination,
but it is unclear if this distinction improves the prognosis
[27, 30]. A study by Biederer et al. suggested that men and
smokers were more likely to have UIP, with a trend toward
purely reticular ﬁndings on HRCT as the number of pack
years increases [31].
Pathologic ﬁndings consistent with NSIP were found to
have predominantly ground glass inﬁltrates on HRCT. This
accounts for about a third of the cases of RA-ILD [26]. NSIP
is a pattern more often found in women and nonsmokers,
and it suggests active alveolar inﬂammation. Consequently,
there is usually a favorable response to immunosuppressive
medications, and prognosis is much better with survival
estimates greater than 80% at 5 years from diagnosis [32].
Bronchiolitis obliterans-organizing pneumonia (BOOP)
occurs less frequently in about 10% of patients, and it
carries a similarly good prognosis as NSIP [33]. Hallmark
features on HRCT include subpleural consolidation with
patchy ground glass inﬁltrates. All of the other ILD his-
tologic subtypes have been reported in RA-ILD including
lymphocytic interstitial lung disease (LIP), which may have
peribronchiolar or centribular nodules and cystic lesions,
as well as the more diﬀuse diseases including desquamative
interstitial pneumonitis(DIP),acuteinterstitial pneumonitis
(AIP), and respiratory bronchiolitis-interstitial lung disease
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Open lung biopsy is the only deﬁnitive procedure to
accurately diagnose an interstitial lung disease, but this
is rarely necessary in RA-ILD as suggested by the joint
ATS-ERS statement regarding the evaluation of interstitial
lung disease in collagen vascular diseases [34]. Additionally,
there may be a 20% increase in mortality if an open lung
biopsy is performed in the setting of an acute exacerbation
of ILD [35]. We do occasionally employ transbronchial
biopsies in conjunction with BAL in an attempt to exclude
other coexisting infectious, granulomatous, or eosinophilic
diseases, butwe nevermakea determinationofthehistologic
injury of an ILD based on this information. It is not
uncommon to obtain a pathologic reading of NSIP although
the leading edge of the injury or a biopsy from another
lung segment may be more consistent with UIP [27]. In
general, we focus on a thorough history to evaluate for other
potential causes of the radiologic ﬁndings and then proceed
with bronchoscopy for BAL with or without transbronchial
biopsies to exclude an alternative diagnosis as described
above.
5.DifferentialDiagnosis
inEstablishedDisease
Once a diagnosis has been rendered, the real challenge
begins. As our index case for this paper illustrates, a clinical
worsening in the context of established disease presents one
of the most diﬃcult aspects of care in RA-ILD. We generally
deﬁne a clinical worsening as the onset of fever, cough, or
new/progressive dyspnea on exertion, and/or a decline in the
forced vital capacity (FVC) by 10% or the DLCO by 15%
[34].
Infection remains the leading cause of death in RA,
accounting for 20–30%of the mortality [36, 37]. Methotrex-
ate is the most extensively reported medication associated
with pulmonary drug toxicity, but almost every medication
available for the treatment of RA has been implicated in the
development of pneumonitis. An often, overlooked possibil-
ity for clinical worsening is environmental or occupational
exposures. There are clinical characteristics that increase the
likelihood of each of these possibilities in any given patient,
and alloftheseneed tobe exploredbeforedetermining thata
clinical worsening is attributable to the underlying RA-ILD.
6.InfectiousComplications
RA patients on immunosuppressive therapy are at an
increased risk of developing lower respiratory tract infec-
tions, particularly if they have pre-existing lung disease.
Many infectious organisms, includingmycobacterium avium,
mycobacterium tuberculosis,a n dpneumocystis jirovecii,a s
well as fungal pathogens can have a radiologic appearance
that mimics RA-ILD with increased ground glass and
interstitial inﬁltrates. An additional consideration is that
chronic prednisone use increases the risk of hospitalization
for pneumonia in RA patients in a dose-dependent fashion
with doses greater than 10mg/day more than doubling the
risk [38]. Another study highlighted an increased risk of
pneumocystis pneumonia in patients taking as little as 15mg
o fp r e d n i s o n ep e rd a yf o rm o r et h a n8w e e k ss u g g e s t i n gt h a t
the use of trimethoprim-sulfamethoxazole as prophylaxis in
these patients may be beneﬁcial [39].
It is also important to note that reactivation of tuber-
culosis in the setting of anti-TNF-α agents can occur and
manifest with pulmonary inﬁltrates, but it appears that
extrapulmonary TB may be more common in this setting
occurring in 65% of cases and manifesting as disseminated
or hepatosplenic disease or even TB meningitis [40]. It
is possible to develop disseminated tuberculosis on anti-
TNF-α agents despite a negative PPD in patients already
receiving mild immunosuppressive medications. This has
prompted the British Thoracic Society to recommend an
individual risk-beneﬁt assessment in these patients based on
the estimated annual risk of MTB multiplied by a factor of
5[ 41]. If disseminated MTB is suspected, sampling multiple
sites is recommended since the diagnostic yield from sputum
or BAL culture is reported as 70% or less [42].
Any suspicion of an infectious complication necessitates
a prompt and thorough investigation. Fever is a common
manifestation of drug-induced pneumonitis, and so it is not
deﬁnitive evidence of an infectious complication. Immuno-
suppressive medications may prevent a robust leukocyte
response to an infectious organism, so our approach to the
patient with pulmonary inﬁltrates often incorporates early
bronchoalveolar lavage in addition to routine blood and
urine cultures.
7.Drug-InducedPneumonitis
A number of medications used to treat RA have been
associated with the development of pulmonary toxicity. We
will brieﬂy describethemainpulmonary toxicitiesassociated
with each drug class and explore the risk factors for diﬀuse
pneumonitis in the case of methotrexate and the anti-TNF-
α biologic agents. Table 2 is provided to summarize these
toxicities.
Environmental Toxins. As our index case would suggest, a
thorough review of potential environmental toxins needs to
be explored. There are over 300 environmental exposures
that can increase the odds of developing a hypersensitiv-
ity pneumonitis (extrinsic allergic alveolitis) [73]. Speciﬁc
questions during the clinical history should address possible
inhaled allergens in the home or work place including
mold, dusts, chemicals, and pet dander. In particular, our
patient kept cockatiels as house pets putting her at risk for
bird fancier’s lung. Other examples include farmer’s lung
caused by thermophilic actinomycetes, lab worker’s lung due
to rodent antigens, and epoxy-resin lung due to phtalic
anhyhdride [73].
Less than 20% of people with known exposures actually
develop extrinsic allergic alveolitis, but acute symptoms
included dyspnea, cough, and malaise and fever in some
patients [74]. Chronic exposure can lead to pulmonary
ﬁbrosis [74]. HRCT will often demonstrate bilateral ground6 Pulmonary Medicine
glass opacities and/or centrilobular nodules similar to RA-
ILD [75]. If there is a known exposure, blood tests for
serum precipitins to the suspected antigen are indicated.
The ﬁnding of poorly formed noncaseating granulomas
in specimens obtained by transbronchial biopsy can be
helpful since these are atypical in RA-ILD as well as MTX
pneumonitis where BAL also shows a lymphocytosis similar
to hypersensitivity pneumonitis [73]. If a diagnosis of
hypersensitivity pneumonitis is rendered, antigen avoidance
can be curative, but it often takes up to three weeks to
recover from an acute episode, and chronic damage may be
irreversible. Steroid therapy may hasten the improvement in
symptoms.
Malignancy. The presence of RA-ILD increases the odds of
developing lung cancer, but immunosuppression itself can
also raise the cancer risk [28]. Diﬀuse inﬁltrates may actually
represent hematogenous or more likely lymphangitic spread
of an underlying malignancy. While this may be a rare
complication, it is one that should be considered when a
patient seemingly fails to respond to treatment. Additionally,
BALincombinationwithtransbronchial biopsymay provide
the correct diagnosis in cases of lymphangitic spread.
7.1. Nonsteroidal Anti-Inﬂammatory Drugs (NSAIDs). In
high doses, NSAIDs have been implicated in the devel-
opment of diﬀuse pulmonary inﬁltrates. In approximately
10–15% of cases, these inﬁltrates were simply pulmonary
edema,butoftentheseinﬁltratesreﬂectanacuteeosinophilic
pneumonia [43]. In fact, a review by Goodwin and Glenny
found naproxento be theNSAIDmost commonlyassociated
with acuteeosinophilic pneumonia, butthere were also cases
associated with just any NSAID [44]. Thankfully, the acute
inﬂammation associated with these medications does not
typically translate into chronic ﬁbrotic lung disease, and
withdrawal oftheoﬀendingagentwith orwithoutadditional
steroid therapy resolves the inﬂammatory response.
7.2. Gold Salts and Penicillamine. Gold salts and penicil-
lamine seem to have fallen out of favor with the advent
of methotrexate and the newer biologic agents, but a few
patients continue to use these medications. The classic pul-
monary toxicities associated with these drugs include inter-
stitial pneumonitis, bronchiolitis obliterans with or without
organizing pneumonia, pulmonary renal syndromes, and
diﬀuse alveolar damage [45–47].
7.3. Methotrexate. The most frequently implicated RA drug
leading to pulmonary toxicity is methotrexate (MTX), but
the estimated risk of developing MTX pneumonitis may
actually be relatively low at doses of 20–25mg/week. One
study found that only 3% of 130 patients followed for
seven years actually developed MTX-induced pulmonary
toxicity[48].Unfortunately,thesubsetofpatientsdeveloping
MTX pneumonitis faced a possible 20% increased mortality
rate especially if the drug toxicity occurred in the ﬁrst six
monthsoftreatment[49].Consequently,attemptstoidentify
patients at risk for pneumonitis should be an important
therapeutic goal.
Saravanan and Kelly found that the greatest predictor
for the development of pneumonitis is pre-existing pul-
monary disease, with a baseline abnormality in the diﬀusing
capacity less than 70% of predicted incurring a 10-fold
increased risk of MTX drug toxicity [50]. Tobacco abuse,
hypoalbuminemia, and previous use of DMARDs including
sulfasalazine, gold salts, or D-penicillamine also have large
attributablerisks[51].Minor riskfactors includingadvanced
age,diabetesmellitus,andRApleuropulmonaryinvolvement
increase the risk for MTX pneumonitis [37, 52, 53]. Our
current recommendation is to obtain pulmonary function
tests prior to the institution of MTX, and if the DLCO
is less than 70% of predicted, and an HRCT shows any
evidence of pleural or interstitial thickening that another
agent considered.
If treatment has already commenced, several clinical
parameters can be monitored for the development of acute
MTX drug toxicity.Surprisingly, routine surveillance ofPFTs
is not useful in predicting drug toxicity, perhaps due to
the acute onset of symptoms [54, 55]. However, duration
of therapy has some clinical utility, since roughly half of
patients that are going to develop MTX drug toxicity will be
symptomatic within the ﬁrst 6–8 months of treatment with
10% of those patients developing symptoms in the ﬁrst 10
weeks [49]. Low-grade fever is the most prevalent symptom,
reported in greater than 90% of patients. Roughly 80% of
patients also developed a dry, nonproductive cough with the
vast majority of these patients also reporting dyspnea on
exertion [49].
Fever should prompt a thorough investigation for an
infectious etiology, and if bronchoscopy is employed, a
bronchoalveolar lavage cell count and ﬂow cytometry can
be useful. The lavage ﬂuid will often show a shift away
fromaneutrophiliccelltypetoapredominantlylymphocytic
inﬁltrate, with an increased CD4:CD8 ratio [56, 57].
Additionally, a small study by Inokuma et al. revealed a
decline in the serum absolute lymphocyte count below
500cells/mm3 was closely associated with MTX drug toxicity
[58].Imaging with HRCTcharacteristically displays a diﬀuse
interstitial pattern in greater than 93% of patients with MTX
pneumonitis. Pleural thickening and less commonly pleural
eﬀusions were also found in a small subset of patients [49].
While it is exceedingly unnecessary, an open lung biopsy can
help distinguish between RA-ILD and MTX pneumonitis. In
general, MTX pneumonitis will have features of acute and
organizing diﬀuse alveolar damage with cellular interstitial
inﬁltrateswithorwithoutgranulomas[59].Thispatternmay
also be seen in some infections but generally diﬀers from
the classic pathologic features of UIP and NSIP in RA-ILD.
However, given the availability of other medications to treat
RA, open lung biopsy is rarely necessary.
Two other patterns of chronic injury have been reported
as well. A few patients have developed an insidious alveolar
ﬁ b r o s i si nt h ea b s e n c eo fs y s t e m i cs y m p t o m sa sw e l la sa
persistent chronic cough that were relieved with cessation of
MTX therapy [57, 60]. Additionally, there are several studies
that have shown a decrease in the FEV1:FVC ratio and anPulmonary Medicine 7
Table 2: Common pulmonary drug toxicities and associated risk factors associated with medications used to treat rheumatoid arthritis.
Medication Pulmonary toxicity Risk factors
NSAIDS
Noncardiogenic pulmonary edema, High-dose treatment
Acute eosinophilicpneumonia,
Interstitial pneumonitis
Gold salts
Interstitial pneumoitis, bronchiolitis obliterans
with or without organizing pneumonia,
pulmonary renal syndrome, diﬀuse alveolar
damage
Unknown, possible genetic association
and cumulative ingestion >500mg gold
D-penicillamine Bronchiolitis obliterans, pulmona renal
syndrome, diﬀuse alveolar damage Unknown
Methotrexate Acute interstitial pneumonitis, pulmonary
ﬁbrosis, pleural thickening,and chronic cough
DLCO < 70% of predicted; tobacco abuse
>25 pack years; hypoalbuminemia; prior
use of DMARDs; RA pleuropulmonary
involvement; advanced age; diabetes
mellitus
Anti-TNF-α biologic agents Interstitial pneumoitis, rapidly progressive
pulmonary ﬁbrosis Possible prior RA-ILD
Leﬂunomide Interstitial pneumonitis Loading dose of leﬂunomide; pre-existing
ground glassinﬁltrates on HRCT
increased residual volume as the most commonly reported
ﬁndings on PFTs of patients on chronic MTX therapy [54,
61, 62].
If acute or chronic toxicity is suspected, withdrawal
of MTX is indicated. Once infection has been excluded,
treatment of the acute toxicity with supportive care is
generally suﬃcient. In more severe or life-threatening cases,
pulse dose glucocorticoids at 1mg/kg/day can accelerate the
resolution and should be strongly considered [63]. However,
if the response to glucocorticoid therapy is inadequate,
the addition of azathioprine or cyclophosphamide can
dramatically improve the clinical response in some cases
[64, 65]. If a patient develops acute toxicity, rechallenge with
MTX is ill advised as the study by Kremer et al. uncovered
mortality rates as high as 50% in this setting [49].
7.4. Leﬂunomide. Leﬂunomide was initially reported to
cause pneumonitis similar to MTX in Asian populations
suggesting a genetic predisposition to pulmonary toxicity
[66]. However, case reports from Australia, Germany, and
the UK have expanded the awareness of pulmonary toxicity
with leﬂunomide use [67]. In a comprehensive evaluation of
theexistingliterature,pulmonarytoxicityoccurredwithin12
weeks of the initiation of therapy in all patients that received
a loading dose of leﬂunomide and most patients who had
pre-existing ILD [67–69]. The mortality associated with the
pneumonitis was reported as 19% predominantly occurring
in the subset of patients with previously noted ground glass
inﬁltrates on HRCT [67].
7.5. Anti-TNF-α Biologic Agents. There are case reports of
patientsinitiated ontreatment with inﬂiximab, adalimumab,
or etanercept who have developed rapidly progressive and
sometimes fatal pulmonary ﬁbrosis [70, 71]. Recently, data
from the British Society for Rheumatology’s Biological
Register (BSRBR) revealed that while the overall mortality
was no diﬀerent between anti-TNF-α agents and DMARDs,
mortality from ILD was nearly tripled in patients on anti-
TNF-α therapy compared to control patients on DMARDs
alone [72]. The authors listed some potential problems with
the study that may account for that ﬁnding, but it appears
that pulmonary toxicity associated with these medications
is an increasingly recognized problem. More studies will be
needed to determine which patients may be at risk for this
complication.
8.TreatmentofRA-ILD
Once a diagnosis of RA-ILD has been made, treatment
is generally focused on controlling the systemic disease
with immunosuppressive agents while tailoring therapy to
the underlying histopathologic subtype. If characteristics of
NSIP or BOOP predominate the radiologic appearance with
ground glass inﬁltrates on HRCT, glucocorticoids alone may
be eﬀective [76]. We follow a standardized protocol set forth
by Lazor et al. in which patients received 0.75mg/kg/day
prednisone during the initial four weeks of treatment, then
0.5mg/kg/day for the next four weeks, then 20mg/day for
four weeks tapering to 10mg/day for the next 6 weeks, and
then 5mg/day for 6 weeks [77].
A deﬁnitive response to treatment is deﬁned as a 10%
improvement in the FVC or 15% improvement in the DLCO
at 12 weeks [32]. Based on recent data from Zappala et al.
we continue therapy even if there is a marginal degree of
improvement (5–10% in FVC or 10–15% in DLCO) [78]. If
the patient meets criteria for improvement, we check thiop-
urinemethyltransferase (TPMT)activity levelsandifnormal
initiate steroidsparing therapy with azathioprine 50mg daily
graduallyincreasingthedoseto2-3mg/kg/day[79].IfTPMT
activity is decreased, cyclosporine is substituted at a dose of
2.5mg/kg/daydividedtwicedaily[80].IftheFVCandDLCO8 Pulmonary Medicine
remain stable with quarterly PFT assessments over a two-
year period, we consider this evidence that progression of
disease has been halted, at which time it may be reasonable
to reassess the medical regimen [32].
If there is evidence of reticular markings and honey-
combing suggesting UIP, we still attempt a trial of immuno-
suppressivetherapyasdescribedabove,butwe alsotreatwith
N-acetylcysteine 600mg three times daily based on clinical
studies in idiopathic pulmonary ﬁbrosis [81]. Cyclophos-
phamide (2mg/kg/day orally) is initiated in conjunction
with lower-dose prednisone (0.25mg/kg/day) for steroid
nonresponders [82]. If they respond, therapy is continued
f o r1 8m o n t h st o2y e a r sa tw h i c hp o i n tt h em e d i c a lr e g i m e n
may be reconsidered or therapy can continue indeﬁnitely.
Appropriately selected non-responders are referred for lung
transplantation.
One additional challenge involves patients referred for
an evaluation of ILD who have occult autoimmune disease.
This aﬀects about 10% of patients who ultimately go on to
develop systemic features of rheumatoid arthritis [83]. If the
anti-CCP antibodies are positive, we will treat the interstitial
lung disease as delineated above and refer to rheumatology
for further evaluation and management.
9.Treatmentof anRA-ILDExacerbation
An ILD exacerbation is generally deﬁned as rapidly dete-
riorating respiratory symptoms within a 30-day period
with evidence of new inﬁltrates (usually new ground glass
opacities) and exclusion of an identiﬁable cause [84]. The
absolute risk of an acute exacerbation is not well established,
but based on the limited data of acute exacerbations in
collagen vascular diseases, possibly as many as 20% of
patients with RA-ILD will experience an acute exacerbation
with a 1-year incidence as high as 2.58% [85]. By the time
patients present to the hospital, hypoxemia may be severe
and a terminal outcome may be eminent [85, 86].
Once alternative explanations for a clinical worsening,
such as infection and/or drug reaction, have been excluded,
treatment is dictated by the underlying histopathology. As
common with many rare diseases, there is a paucity of well-
designed clinical trials to guide therapy in RA-ILD, but if
the underlying histopathology is NSIP or BOOP, there is
a reasonable probability for a sustained clinical response
to glucocorticoid treatment alone or in conjunction with
other immunosuppressive agents [76]. However, ground
glass inﬁltrates on the background of UIP often herald the
development of diﬀuse alveolar damage, and the ensuing
mortality approaches 80–100% [85–88]. The only evidence
to support treatment in this cohort comes from a handful of
isolatedcasereports,whilemorerobustobservationalstudies
have demonstrated a consistently poor prognosis [85–88].
Giventhelackofevidencetosupportimmunosuppressionin
UIP, decisions to treat must be made on an individual basis.
We generally initiate treatment with IV methylpred-
nisolone at a dose of 1mg/kg/day for 3 days followed by oral
prednisolone1mg/kg/day.Ifthereisnoevidenceofimprove-
mentinpaO2/FiO2 ratiooroxygensaturationrescuetherapy
with cyclophosphamide (500–750mg/m2)m a yb ec o n s i d -
ered [89]. Other regimens have employed cyclosporine
3mg/kg/day or tacrolimus 3mg/kg/day in divided doses
in patients unresponsive to cyclophosphamide with some
success in isolated case reports [90, 91]. If the patient
progresses to the point of requiring ventilatory support,
consideration should be given to noninvasive ventilation,
and/or lower PEEP settings and avoidance of recruitment
maneuvers, since PEEP levels >10cm H2O had more than
a 4-fold associated risk of subsequent mortality in one study
of acute ILD exacerbations [92].
10.Other Possible Drug Therapies
10.1. Anticoagulation. In situ thrombosis within the pul-
monary vasculature has been documented in ILD, and a trial
ofanticoagulationwithwarfarin byKuboetal.demonstrated
improved survival in this patient population [93]. This may
be a reasonable medical therapy in patients with extensive
RA-ILD although there are no speciﬁc trials investigating its
use in this patient population.
10.2. N-Acetylcysteine (NAC). NAC is an antioxidant found
to be mildly eﬀective at preventing the decline in lung
function in idiopathic pulmonary ﬁbrosis (IPF) [81]. While
there is no data regarding its use in RA-ILD, its side eﬀect
proﬁle mirrors multivitamins. Since UIP is the predominant
histopathology in RA-ILD and is the hallmark pathologic
ﬁnding in IPF, a dose of 600mg three times daily may be
reasonable to consider in RA-ILD.
10.3. Mycophenolate. This medication has been used for the
treatment of RA-ILDand it appears eﬀective in patients with
early or limited disease at a dose of 1-2mg/day [94, 95].
It does not appear to be that eﬀective in relieving articular
manifestations of the disease, and therefore it needs to be
used in conjunction with DMARD’s in most cases.
10.4. Rituximab. This biologic agent is an anti-CD20 anti-
body licensed for the treatment of RA refractory to anti-
TNF-α therapy. Interestingly, RA-ILD patients with a UIP
histological pattern have increased numbers of CD-20 pos-
itive B cells aggregated around small airways [96]. Although
there are no published trials on the use of rituximab for
RA-ILD, Popa et al. found that RA patients treated with
rituximab for 7 years have not shown any evidence of new
RA-ILD [97]. There are also several cases reporting the
successful use of weekly rituximab for ILD in other forms of
collagen vascular disease [98–101].
Theoptimaltreatmentstrategyremainselusiveduetothe
rare nature of the disease. Hopefully, increased coordination
among multiple academic centers will help advance the
evaluation of novel medications in large, well-conducted,
clinical trials.Pulmonary Medicine 9
11.Conclusion
It is becoming increasingly obvious that RA-ILD is a more
prominent and debilitating manifestation of RA than once
believed. As our index case demonstrated, there are host
of factors that can obscure the diagnosis, but prompt
diagnosis and treatment may delay the progression to end-
stage lung disease. Unfortunately, once RA-ILD has been
diagnosed, any acute worsening engages the clinician in an
often, challenging evaluation process. Is it the disease, the
medications, or some other unrelated but reversible factors
contributing to a decline in lung function?
In our patient, reticular markings and ground glass
opacitieswerepresentinlate2007,butshedidnotexperience
signiﬁcant symptoms for another several months. When she
presented for evaluation, she already had a decline in her
diﬀusing capacity to 61% of predicted. An infectious source
was excluded, and it would have been very easy to attribute
her symptoms to an obvious case of RA-ILD. However,
given her environmental exposures, serum precipitins were
drawn to evaluate for a hypersensitivity pneumonitis. She
was found to have elevated IgG precipitins to cockatiels,
and lymphocytosis was noted on bronchoalveolar lavage.
Given a diagnosis of probable hypersensitivity pneumonitis
she was started on high-dose prednisone, and she removed
her cockatiels from the home. Over the next three months
her DLCO improved to 89%. Her prednisone was tapered
to 10mg daily, and one year later her, DLCO had been
normalized at 98% of predicted.
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